<DOC>
	<DOC>NCT00543634</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin速/medroxyprogesterone (MPA).</brief_summary>
	<brief_title>Study Comparing Premarin速/MPA, PREMPRO速 and Provera速 in Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<criteria>Healthy postmenopausal women aged 35 to 70 years with spontaneous or surgical amenorrhea BMI in the range of 18 to 35 kg/m2 History or presence of hypertension (&gt;139 mm Hg systolic or &gt;89 mm Hg diastolic) History of drug allergy, particularly to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs) Use of any prescription or investigational drug within 30 days before test article administration</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>